Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1233 results
March 2017
-
Press Release
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
Phase III RELAX-AHF-2 study did not meet primary endpoints of reduced cardiovascular death or worsening heart failure in patients with acute heart failure Novartis remains committed to… -
Press Release
Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
New data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment[1] Patients with longer disease duration before… -
Press Release
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
New post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced… -
Press Release
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
Approved based on a first-line Phase III trial that met its primary endpoint of progression-free survival (PFS) at interim analysis due to superior efficacy compared to letrozole alone[1] … -
Press Release
Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)
Three winners, chosen by expert panel at Wired Health 2017 in London, identified innovative approaches to address access challenges in Ghana, the Maldives and the Philippines. Winning ideas… -
Press Release
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
New analysis shows 94% of patients on Cosentyx® regained PASI 75, with up to 80% of patients regaining PASI 90 to 100 after only 16 weeks of retreatment[1] Cosentyx has shown superior and… -
Press Release
New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine
Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®*Comprehensive development program show potential of GP2017…
February 2017
-
Press Release
Novartis Aktionäre genehmigen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats
Aktionäre genehmigen für 2016 die 20. Dividendenerhöhung in Folge auf CHF 2,75 pro Aktie (+2%) - dies entspricht einer Rendite von 3,5% und einer Ausschüttungsquote von circa 69% des Free Cashflow… -
Press Release
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
Shareholders approve 20th consecutive dividend increase to CHF 2.75 (+2%) per share for 2016; representing a 3.5% yield and approximately 69% payout of free cash flow Dr. Joerg Reinhardt… -
Press Release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration lors de l'Assemblée générale annuelle
Les actionnaires approuvent la 20e hausse consécutive du dividende, à CHF 2,75 (+2 %) par action au titre de l'exercice 2016. Cela représente un rendement de 3,5 % et une distribution du free cash-… -
Press Release
Novartis receives positive CHMP opinion for Tafinlar® + Mekinist® in BRAF-positive non-small cell lung cancer (NSCLC) patients
If approved, Tafinlar + Mekinist will be the first targeted therapy specifically for NSCLC patients with a BRAF V600 mutation CHMP opinion based on positive data from pivotal study of patients… -
Press Release
Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
Priority Review based on Phase III study results showing 16.6 month median progression-free survival in previously untreated ALK+ metastatic NSCLC patients on Zykadia vs. 8.1 months treated with…